German science and technology giant Merck on Thursday said it is confident of returning to medium-term growth after a ...

Dr. Steven-Huy Han, a UCLA liver specialist, has prescribed Ocaliva to a handful of patients, although he’s not sure it helps ...

Promethean, a leading global education technology company and brand owned by Mynd.ai, Inc. , won this year's Tech & Learning Awards of Excellence: Back to School 2024 in the Primary category from Tech ...

Speakers include representatives from AstraZeneca, Bristol Myers Squibb, Certara, GSK, IQVIA, Merck, Pfizer, and Roche ... Founded in 1964 with headquarters in Washington, D.C., and offices in Europe ...

German science and technology group Merck is open to more acquisitions for its Life Science business after announcing in May ...

Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...

Merck also changed the outlook for its Healthcare business to "slight growth", compared to a previously expected ...

EXEL is set to evaluate investigational zanzalintinib in combination with Merck;s Keytruda (pembrolizumab) and Welireg in head and neck cancer and renal cell carcinoma, respectively. ALAMEDA ...

The U.S. Food and Drug Administration approved Astellas' therapy to treat a type of gastric cancer, the health regulator's ...

Spinogenix is using small molecule drugs to regenerate synapses in patients with ALS, Alzheimer's disease, schizophrenia, ...

Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...

Merck & Co's efforts to diversify its cancer pipeline beyond immunotherapy blockbuster Keytruda have taken a big step forward with a wide-ranging alliance with China's Kelun-Biotech that spans ...